| Zydus Pharmaceuticals (USA) Inc. |
83513001001 |
Beizray (Docet) Inj 80mg/4mL (160mg Kit) |
2025-03-03 |
7920.0000 |
None |
1 |
937639 |
None |
None |
None |
None |
None |
None |
Acquisition date and price are not applicable. Zydus has entered “937,639” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Beizray is indicated for the treatment of patients with locally advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer after failure or prior platinum based chemotherapy, for the tratment of patients with metastatic castration resistant prostate cancer, for the treatment of patients with advanced gastric adenocarcinoma and also for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. The following websites were used to come up with our patient estimate - (https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#:~:text=Incidence%20and%20Mortality,-Estimated%20new%20cases&text=Breast%20cancer%20is%20the%20most,section%20in%20Breast%20Cancer%20Screening.), (https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer-stat-bite.html#:~:text=What%20to%20know,males%20died%20from%20prostate%20cancer), (https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html#:~:text=Overall%2C%20the%20chance%20that%20a,the%20past%20decade%20in%20women.), (https://www.cancer.org/cancer/types/stomach-cancer/about/key-statistics.html#:~:text=About%2030%2C300%20new%20cases%20of,risk%20factors%20for%20stomach%20cancer), (https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet#:~:text=Researchers%20estimated%20that%20more%20than,cancer%20are%20much%20less%20common.) |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174503 |
Dasatinib 100mg Tablets 30 Count |
2025-03-03 |
3120.1200 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174603 |
Dasatinib 140mg Tablets 30 Count |
2025-03-03 |
3120.1200 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174106 |
Dasatinib 20mg Tablets 30 Count |
2025-03-03 |
1731.1600 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174206 |
Dasatinib 50mg Tablets 30 Count |
2025-03-03 |
3462.3200 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174306 |
Dasatinib 70mg Tablets 30 Count |
2025-03-03 |
3462.3200 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |
| Zydus Pharmaceuticals (USA) Inc. |
70710174403 |
Dasatinib 80mg Tablets 30 Count |
2025-03-03 |
3120.1200 |
None |
1 |
70000 |
None |
None |
None |
None |
None |
None |
This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Zydus has entered “70,000” in the “Estimated Number of Patients” column, however: (1). Zydus’ role as generic manufacturer is to provide products to our customers, not to determine what conditions our products will be used or the number of patients in the US that could potentially have the condition for which our products treat. (2). We do not estimate the number of patients that may be prescribed our products neither by state nor nationally. Manufacturing volumes are based on an estimated market share along with IQVIA data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients. (3). Zydus neither collects nor uses estimated patient information in our normal course of business. (4). Dasatinib is indicated for the treatment of newly diagnosed or previously treated Philadelphia chromosome positive chronic myeloid leukemia (Ph + CML). As per the Novartis Scemblix website (https://us.scemblix.com/about-ph-cml/ph-cml-chronic-phase) as of 2021, it was estimated that nearly 70,000 people in the United States were living with Ph+CML. For this reason we have put in a number of 70,000 in estimated number of patients. |
None |